eGenesis Raises $38M Series A Funding
Summary
eGenesis, a Cambridge, MA-based biotechnology company focused on utilizing genome editing technology to enable xenotransplantation* as a routine medical procedure, raised a $38m Series A financing.In conjunction with the funding, Daniel S. Lynch has joined eGenesis as Executive Chairman.Led by Dr. Luhan Yang, Marc Guell, and seven scientists from Harvard with expertise in genome editing, synthetic biology and transgenic animals, eGenesis is a life sciences company focused on leveraging genome editing technology to deliver effective human transplantable cells, tissues and organs.It is harnessing its CRISPR-based technology platform to deliver safe and effective human transplantable cells, tissues and organs, which are grown in pigs.*Xenotransplantation is the process of grafting or transplanting organs or tissues to humans from other species, and it holds vast potential for filling the medical need for healthy organs for transplantation.